Maxime Chénard-Poirier

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer

Sarah Halford, Gareth J. Veal, Stephen R. Wedge et al. · Clinical Cancer Research · 2023 · 219 citations · Full text

Medicine, Oncology, Pharmacology +10

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors

Malaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo et al. · European Journal of Cancer · 2017 · 76 citations

Medicine, Hematology, Oncology +16

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Christina Guo, Maxime Chénard-Poirier, Desamparados Roda et al. · The Lancet Oncology · 2020 · 74 citations

Medicine, Oncology, Pharmacology +12

The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation

Bertrand Routy, Caroline Letendre, David Enot et al. · OncoImmunology · 2016 · 72 citations · Full text

Life Sciences, Immunology, Microbiology +17

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal et al. · Journal for ImmunoTherapy of Cancer · 2022 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17